NASDAQ · Drug Manufacturers - Specialty & Generic

HROW (HROW) Stock

$39.09 +0.83% NASDAQ: HROW Healthcare

Valuation

MetricValue
Price$39.09
Market Cap$1.46B
P/E Ratio14.50
P/B Ratio50.42
P/S Ratio5.39
EPS (TTM)$2.72
52-Week High$54.85
52-Week Low$28.54
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.43%
ROA3.14%
ROCE75.00%
Gross Margin74.11%
Operating Margin10.47%
Net Margin-5.57%
Debt/Equity10.47
Current Ratio2.21

Annual Financials (USD)

Metric20212022202320242025
Revenue$72.0M$89.0M$130.0M$200.0M$272.0M
Operating Profit$2.0M$2.0M$0$9.0M$39.0M
Net Profit$-18.0M$-14.0M$-24.0M$-17.0M$-5.0M
EPS$-0.69$-0.51$-0.75$-0.49$-0.14
Op Margin2.2%2.2%0.3%4.4%14.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$98.0M$157.0M$312.0M$389.0M$399.0M
Total Liabilities$87.0M$130.0M$242.0M$320.0M$347.0M
Cash$42.0M$96.0M$74.0M$47.0M$73.0M
Borrowings$78.0M$112.0M$191.0M$229.0M$252.0M

Latest News

Harrow Expands Retina Portfolio With US Launch of Byooviz MT Newswires · Jul 1, 2026 Harrow Announces Commercial Launch of BYOOVIZ® in the United States GlobeNewswire · Jul 1, 2026 Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow Business Wire · Jul 1, 2026 GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 Insider Monkey · Jun 23, 2026 Is Harrow, Inc. (HROW) A Good Stock To Buy Now? Insider Monkey · Jun 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$5.0M$2.0M$4.0M$-22.0M$44.0M
Investing Cash Flow$-47.0M$-10.0M$-305.0M$-72.0M$-7.0M
Financing Cash Flow$-19.0M$0$-13.0M$-1.0M$-25.0M
Net Cash Flow$38.0M$54.0M$-22.0M$-27.0M$26.0M
Free Cash Flow$-23.0M$-6.0M$-149.0M$-61.0M$43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio20.54
EV / EBITDA41.36
FCF Yield0.99%
Quick Ratio2.30
Interest Coverage1.63
Return 1Y13.40%
Return 3Y97.08%
Return 5Y407.26%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALVOAlvotech $3.16 +3.10% -10.76 $1.07B 0.00%
AMPH $20.22 +1.40% 12.02 $891.56M 0.00%
BLFS $32.15 +2.78% -96.00 $1.57B 0.00%
COLL $35.58 +0.54% 17.33 $1.15B 0.00%
DVAXDynavax Technologies Corporation $15.50 +0.00% -40.79 $1.82B 0.00%

About HROW

HROW is led by CEO Mark L. Baum, employs 382 people, headquartered in US, publicly traded since 2007.

HROW stock trades at $39.09 with a market capitalization of $1.46B. The stock is valued at a price-to-earnings (P/E) ratio of 14.50, price-to-book of 50.42, price-to-sales of 5.39. Over the past 52 weeks the stock has ranged between $28.54 and $54.85, and currently trades 28.7% below its 52-week high.

On profitability, HROW generates a return on equity (ROE) of -35.43%, return on capital employed of 75.00%, an operating margin of 10.47%, a net profit margin of -5.57%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides